High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
Channing J PallerMarianna L ZahurakAdel MandlNicole A MetriAliya LaljiElisabeth I HeathWilliam Kevin KellyChristopher J HoimesPedro C BarataJason TakseyDominique A GarrisonKartick PatraGinger L MilneNicole M AndersJulie M NaurothJennifer N DurhamCatherine Handy MarshallMark C MarkowskiMario A EisenbergerEmmanuel S AntonarakisMichael A CarducciSamuel R DenmeadeMark LevinePublished in: Cancer research communications (2024)
This is the first randomized, placebo-controlled, double-blind trial to evaluate HDIVC in cancer treatment. The addition of HDIVC to docetaxel in patients with mCRPC does not improve PSA response, toxicity, or other clinical outcomes compared with docetaxel alone. The routine use of HDIVC in mCRPC treatment is not supported outside of clinical trials.
Keyphrases
- placebo controlled
- double blind
- phase iii
- clinical trial
- phase ii
- high dose
- study protocol
- locally advanced
- phase ii study
- prostate cancer
- squamous cell carcinoma
- open label
- stem cell transplantation
- low dose
- oxidative stress
- small cell lung cancer
- clinical practice
- radiation therapy
- randomized controlled trial
- combination therapy
- middle aged
- replacement therapy
- rectal cancer